Effects of deferiprone on immune status and cytokine pattern in thalassaemia major

Area of Science:

• Immunology
• Hematology
• Pharmacology

Background:

• Thalassaemia major is a severe inherited blood disorder requiring lifelong treatment.
• Iron overload is a common complication in thalassemia major patients due to frequent blood transfusions.
• Iron chelation therapy, such as with deferiprone (L1), is crucial for managing iron overload but may impact immune function.

Purpose of the Study:

• To investigate potential immunological abnormalities in thalassemia major patients receiving deferiprone (L1) treatment.
• To assess the impact of L1 therapy on specific immune cell populations and cytokine levels.

Main Methods:

• A longitudinal observational cohort study design was employed.
• Immune parameters, including CD8+ lymphocyte counts, CD4/CD8 ratio, and cytokine levels (TNF-alpha, IL-2, IL-2sRalpha, IL-6, IL-10), were monitored over time.
• Measurements were taken before and at various time points during L1 treatment.

Main Results:

• Elevated CD8+ lymphocytes and a low CD4/CD8 ratio were observed prior to L1 treatment, normalizing after 3 months.
• Elevated levels of TNF-alpha, IL-2, and IL-2sRalpha were detected before treatment, returning to normal ranges after 12, 6, and 3 months of L1, respectively.
• IL-6 levels were normal at baseline, and IL-10 increased over time but remained within normal limits.

Conclusions:

• Deferiprone (L1) treatment appears to resolve pre-existing immunological abnormalities in thalassemia major patients.
• L1 therapy effectively normalizes lymphocyte subsets and key pro-inflammatory cytokines, suggesting a beneficial immunomodulatory effect.
• These findings support the safety and efficacy of L1 in managing thalassemia major, with positive implications for immune system recovery.